| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor Protein-Tyrosine Kinases | 4 | 2018 | 159 | 1.660 |
Why?
|
| Lung Neoplasms | 11 | 2018 | 2369 | 1.090 |
Why?
|
| Glucuronosyltransferase | 7 | 2008 | 186 | 1.010 |
Why?
|
| Exons | 5 | 2018 | 453 | 0.890 |
Why?
|
| Alternative Splicing | 2 | 2018 | 214 | 0.670 |
Why?
|
| Vitamin D Deficiency | 6 | 2018 | 104 | 0.670 |
Why?
|
| Sequence Analysis, RNA | 2 | 2018 | 241 | 0.660 |
Why?
|
| Extracellular Space | 1 | 2017 | 92 | 0.570 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 923 | 0.570 |
Why?
|
| Protein Isoforms | 1 | 2017 | 281 | 0.540 |
Why?
|
| Proto-Oncogene Proteins c-met | 6 | 2010 | 200 | 0.540 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 872 | 0.450 |
Why?
|
| Serotonin | 3 | 2005 | 221 | 0.450 |
Why?
|
| Trigonella | 1 | 2012 | 1 | 0.420 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.420 |
Why?
|
| Calcitriol | 1 | 2013 | 173 | 0.400 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 58 | 0.400 |
Why?
|
| Vitamin D | 5 | 2018 | 269 | 0.380 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2015 | 2424 | 0.380 |
Why?
|
| Phytotherapy | 1 | 2012 | 136 | 0.380 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 274 | 0.360 |
Why?
|
| Autophagy | 1 | 2012 | 160 | 0.360 |
Why?
|
| Insulin Resistance | 1 | 2013 | 361 | 0.360 |
Why?
|
| Plant Extracts | 1 | 2012 | 245 | 0.350 |
Why?
|
| Glucuronides | 5 | 2008 | 34 | 0.350 |
Why?
|
| Cell Line, Tumor | 8 | 2018 | 2607 | 0.350 |
Why?
|
| Liver | 4 | 2013 | 1216 | 0.300 |
Why?
|
| Saudi Arabia | 9 | 2019 | 16 | 0.290 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2015 | 112 | 0.270 |
Why?
|
| Pregnancy Trimester, First | 2 | 2018 | 63 | 0.270 |
Why?
|
| Hydroxytryptophol | 1 | 2004 | 1 | 0.240 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 155 | 0.230 |
Why?
|
| ErbB Receptors | 4 | 2011 | 499 | 0.220 |
Why?
|
| Obesity | 4 | 2014 | 977 | 0.210 |
Why?
|
| Humans | 33 | 2019 | 90568 | 0.200 |
Why?
|
| Body Mass Index | 3 | 2014 | 775 | 0.180 |
Why?
|
| Paxillin | 2 | 2013 | 58 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 2364 | 0.170 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2015 | 1129 | 0.170 |
Why?
|
| Receptors, Growth Factor | 2 | 2010 | 52 | 0.170 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2019 | 7 | 0.160 |
Why?
|
| Transcription, Genetic | 2 | 2013 | 1161 | 0.150 |
Why?
|
| Diabetes, Gestational | 1 | 2018 | 44 | 0.140 |
Why?
|
| Dietary Supplements | 1 | 2018 | 124 | 0.140 |
Why?
|
| Biomarkers | 5 | 2019 | 1797 | 0.140 |
Why?
|
| Pharmacogenetics | 3 | 2005 | 437 | 0.140 |
Why?
|
| Child | 8 | 2019 | 7216 | 0.130 |
Why?
|
| Adolescent | 9 | 2018 | 9353 | 0.130 |
Why?
|
| Male | 16 | 2018 | 42931 | 0.130 |
Why?
|
| Dairy Products | 1 | 2015 | 11 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2005 | 3765 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 3 | 2015 | 961 | 0.120 |
Why?
|
| Sequence Deletion | 1 | 2015 | 205 | 0.120 |
Why?
|
| Dyslipidemias | 1 | 2015 | 107 | 0.120 |
Why?
|
| Parathyroid Hormone | 1 | 2015 | 221 | 0.110 |
Why?
|
| Adult | 13 | 2018 | 26940 | 0.110 |
Why?
|
| Genotype | 3 | 2009 | 1855 | 0.110 |
Why?
|
| Oxazepam | 2 | 2004 | 3 | 0.110 |
Why?
|
| Middle Aged | 11 | 2018 | 26327 | 0.110 |
Why?
|
| Microsomes, Liver | 2 | 2004 | 49 | 0.110 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Calcium | 2 | 2015 | 1182 | 0.110 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 539 | 0.110 |
Why?
|
| Indoles | 3 | 2009 | 306 | 0.110 |
Why?
|
| Piperazines | 3 | 2009 | 284 | 0.110 |
Why?
|
| Receptor, Insulin | 1 | 2013 | 54 | 0.110 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2013 | 55 | 0.110 |
Why?
|
| Eugenol | 1 | 2012 | 2 | 0.110 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2012 | 3 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 289 | 0.100 |
Why?
|
| Guaiacol | 1 | 2012 | 3 | 0.100 |
Why?
|
| Benzaldehydes | 1 | 2012 | 4 | 0.100 |
Why?
|
| Sesquiterpenes | 1 | 2012 | 12 | 0.100 |
Why?
|
| Catechols | 1 | 2012 | 9 | 0.100 |
Why?
|
| Female | 15 | 2018 | 46855 | 0.100 |
Why?
|
| Fatty Alcohols | 1 | 2012 | 10 | 0.100 |
Why?
|
| Tissue Distribution | 1 | 2013 | 293 | 0.100 |
Why?
|
| Jurkat Cells | 1 | 2012 | 78 | 0.100 |
Why?
|
| Substrate Specificity | 2 | 2004 | 362 | 0.100 |
Why?
|
| Sulfonamides | 3 | 2009 | 320 | 0.100 |
Why?
|
| Muscles | 1 | 2013 | 192 | 0.100 |
Why?
|
| Vacuoles | 1 | 2012 | 46 | 0.100 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 343 | 0.100 |
Why?
|
| Focal Adhesions | 1 | 2013 | 70 | 0.100 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 56 | 0.100 |
Why?
|
| Calcifediol | 1 | 2012 | 20 | 0.100 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 1460 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 315 | 0.100 |
Why?
|
| Seeds | 1 | 2012 | 59 | 0.100 |
Why?
|
| Sunlight | 1 | 2012 | 28 | 0.100 |
Why?
|
| Diet, High-Fat | 1 | 2013 | 121 | 0.100 |
Why?
|
| Receptors, Calcitriol | 1 | 2013 | 130 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2012 | 64 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 455 | 0.100 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2012 | 184 | 0.090 |
Why?
|
| Aged | 7 | 2012 | 19404 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2009 | 531 | 0.090 |
Why?
|
| Adipose Tissue | 1 | 2013 | 263 | 0.090 |
Why?
|
| Cell Line | 2 | 2012 | 2505 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 348 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2010 | 36 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 728 | 0.080 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.080 |
Why?
|
| RNA, Small Interfering | 4 | 2014 | 558 | 0.080 |
Why?
|
| Animals | 8 | 2014 | 27691 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2012 | 665 | 0.080 |
Why?
|
| Cross-Sectional Studies | 4 | 2018 | 1735 | 0.080 |
Why?
|
| PAX5 Transcription Factor | 1 | 2009 | 33 | 0.080 |
Why?
|
| Exercise | 1 | 2012 | 328 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 1935 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 684 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 282 | 0.080 |
Why?
|
| Vulva | 1 | 2008 | 23 | 0.080 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 349 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 83 | 0.070 |
Why?
|
| Mutation | 5 | 2013 | 4184 | 0.070 |
Why?
|
| Risk Factors | 5 | 2018 | 5580 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 219 | 0.070 |
Why?
|
| Phenotype | 3 | 2015 | 2471 | 0.070 |
Why?
|
| Nutritional Status | 2 | 2018 | 81 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 651 | 0.070 |
Why?
|
| Prevalence | 3 | 2015 | 1251 | 0.070 |
Why?
|
| Mice | 4 | 2014 | 11932 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 723 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 1096 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 3273 | 0.060 |
Why?
|
| Prognosis | 2 | 2012 | 3810 | 0.060 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 1015 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1193 | 0.060 |
Why?
|
| Isoenzymes | 2 | 2003 | 275 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2008 | 2030 | 0.060 |
Why?
|
| Models, Molecular | 1 | 2009 | 1324 | 0.060 |
Why?
|
| Rats, Gunn | 1 | 2004 | 2 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 589 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 827 | 0.060 |
Why?
|
| Oxidoreductases, N-Demethylating | 1 | 2004 | 14 | 0.060 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2004 | 19 | 0.060 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 106 | 0.060 |
Why?
|
| Cats | 1 | 2004 | 305 | 0.060 |
Why?
|
| Bupropion | 1 | 2004 | 21 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 44 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1550 | 0.060 |
Why?
|
| Rats, Wistar | 1 | 2004 | 304 | 0.060 |
Why?
|
| Gene Dosage | 3 | 2009 | 210 | 0.050 |
Why?
|
| Triglycerides | 2 | 2015 | 235 | 0.050 |
Why?
|
| Microsomes | 1 | 2003 | 35 | 0.050 |
Why?
|
| Haplotypes | 1 | 2005 | 638 | 0.050 |
Why?
|
| Anti-Anxiety Agents | 1 | 2002 | 23 | 0.050 |
Why?
|
| Insecta | 1 | 2003 | 52 | 0.050 |
Why?
|
| Cholesterol | 2 | 2015 | 362 | 0.050 |
Why?
|
| Surveys and Questionnaires | 3 | 2018 | 2667 | 0.050 |
Why?
|
| Head and Neck Neoplasms | 1 | 2009 | 1061 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2004 | 328 | 0.050 |
Why?
|
| Young Adult | 3 | 2018 | 6425 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 1074 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2015 | 303 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 491 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 272 | 0.040 |
Why?
|
| Transfection | 2 | 2014 | 910 | 0.040 |
Why?
|
| Pregnancy | 2 | 2018 | 3064 | 0.040 |
Why?
|
| Age Factors | 2 | 2015 | 1871 | 0.040 |
Why?
|
| Vitamin B 12 | 1 | 2019 | 24 | 0.040 |
Why?
|
| Fitness Centers | 1 | 2018 | 1 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 6812 | 0.040 |
Why?
|
| Rats | 1 | 2004 | 4059 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2018 | 232 | 0.040 |
Why?
|
| Fasting | 1 | 2018 | 166 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 898 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2008 | 2337 | 0.030 |
Why?
|
| RNA Interference | 2 | 2008 | 377 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2009 | 742 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 680 | 0.030 |
Why?
|
| Parents | 1 | 2019 | 290 | 0.030 |
Why?
|
| Recommended Dietary Allowances | 1 | 2015 | 2 | 0.030 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2015 | 3 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 23 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 594 | 0.030 |
Why?
|
| Endoglin | 1 | 2014 | 21 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2014 | 85 | 0.030 |
Why?
|
| Eating | 1 | 2015 | 168 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2018 | 846 | 0.030 |
Why?
|
| Random Allocation | 1 | 2014 | 327 | 0.030 |
Why?
|
| Apoptosis | 2 | 2012 | 1723 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2014 | 260 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2014 | 307 | 0.030 |
Why?
|
| Incidence | 1 | 2018 | 1594 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 212 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 692 | 0.030 |
Why?
|
| Ligands | 1 | 2014 | 453 | 0.030 |
Why?
|
| Kinetics | 2 | 2008 | 1550 | 0.030 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 37 | 0.030 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2012 | 25 | 0.030 |
Why?
|
| Lipocalins | 1 | 2012 | 35 | 0.030 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 37 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 467 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2015 | 330 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2012 | 20 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 281 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 161 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2012 | 39 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 294 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 126 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2012 | 171 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 303 | 0.020 |
Why?
|
| Health Surveys | 1 | 2012 | 239 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 24 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 422 | 0.020 |
Why?
|
| Allelic Imbalance | 1 | 2011 | 22 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2014 | 3426 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 660 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 118 | 0.020 |
Why?
|
| Peptides | 1 | 2014 | 661 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2014 | 409 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 78 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 106 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 86 | 0.020 |
Why?
|
| Wound Healing | 1 | 2012 | 365 | 0.020 |
Why?
|
| Cell Survival | 1 | 2012 | 987 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2011 | 344 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1132 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 284 | 0.020 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2009 | 34 | 0.020 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 2009 | 24 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 546 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2009 | 52 | 0.020 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2009 | 34 | 0.020 |
Why?
|
| Deoxycholic Acid | 1 | 2008 | 10 | 0.020 |
Why?
|
| CDX2 Transcription Factor | 1 | 2008 | 7 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1 | 1 | 2008 | 30 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2008 | 66 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 793 | 0.020 |
Why?
|
| Rifampin | 1 | 2008 | 23 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 794 | 0.020 |
Why?
|
| Receptors, Steroid | 1 | 2008 | 42 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 694 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2009 | 252 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2009 | 354 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2008 | 69 | 0.020 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 183 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 309 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2008 | 279 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2008 | 646 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2009 | 819 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2008 | 295 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 4345 | 0.020 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2008 | 141 | 0.020 |
Why?
|
| Cisplatin | 1 | 2009 | 599 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 194 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2009 | 605 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2012 | 781 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2011 | 1873 | 0.020 |
Why?
|
| Nicotine | 1 | 2008 | 202 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2329 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2008 | 570 | 0.020 |
Why?
|
| Caenorhabditis elegans | 1 | 2008 | 232 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 746 | 0.020 |
Why?
|
| Lung | 1 | 2012 | 1305 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 1182 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 1806 | 0.010 |
Why?
|
| Cytochrome P-450 CYP2B6 | 1 | 2004 | 6 | 0.010 |
Why?
|
| Hydroxylation | 1 | 2004 | 18 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 558 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 1286 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2002 | 44 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 2002 | 102 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 318 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2008 | 1688 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 997 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 1138 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 2523 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1919 | 0.010 |
Why?
|
| Neoplasms | 1 | 2009 | 3029 | 0.010 |
Why?
|